{"product_id":"lppla2-elisa-kit-for-human","title":"LpPLA2 ELISA kit (Human)","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e: 96Tests\u003c\/p\u003e\u003cp\u003e\u003cb\u003e# of Times Cited in literature\u003c\/b\u003e: 15\u003c\/p\u003e\u003cp\u003e\u003cb\u003ePrepare Time\u003c\/b\u003e: 1-3 days(please inquire for mutiple units)\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Name\u003c\/b\u003e: LpPLA2\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Full Name\u003c\/b\u003e: Phospholipase A2 Group VII\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAlternative Names\u003c\/b\u003e: PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Species\u003c\/b\u003e: Human\u003c\/p\u003e\u003cp\u003e\u003cb\u003eUniprot\u003c\/b\u003e: Q13093\u003c\/p\u003e\u003cp\u003e\u003cb\u003eGene ID\u003c\/b\u003e: 7941\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFeatured Series\u003c\/b\u003e: SE kit\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFeatured Series Function\u003c\/b\u003e: Detects protein (regular version)\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSpecificity\u003c\/b\u003e: Reactive with Human LpPLA2 \/ Phospholipase A2 Group VII\u003c\/p\u003e\u003cp\u003e\u003cb\u003eMethod\u003c\/b\u003e: Colormetric\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection principle\u003c\/b\u003e: Double-antibody Sandwich\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection\nrange\u003c\/b\u003e: 0.625-40ng\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSensitivity\u003c\/b\u003e: 0.255ng\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay Time\u003c\/b\u003e: 3h\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSample Size\u003c\/b\u003e: 100uL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRecommended\/Predicted\nSample Types\u003c\/b\u003e: Serum, Plasma and other Biological Fluids\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay Precision\u003c\/b\u003e: Intra-Assay: CV\u0026lt;10%, Inter-Assay: CV\u0026lt;12%\u003c\/p\u003e\u003cp\u003e\u003cb\u003eReproducibility test menthod\u003c\/b\u003e: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Phospholipase A2 Group VII (LpPLA2) were tested 20 times on one plate, respectively.\nInter-assay Precision (Precision between assays): 3 samples with low, middle and high level Phospholipase A2 Group VII (LpPLA2) were tested on 3 different plates, 8 replicates in each plate.\nCV(%) = SD\/meanX100\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStorage\u003c\/b\u003e: 4°C for 1 month\/ -20°C for long-term(One year within shelf life)\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShelf-life\u003c\/b\u003e: 12 months\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSpecificity\u003c\/b\u003e: This assay has high sensitivity and excellent specificity for detection of Phospholipase A2 Group VII (LpPLA2).\nNo significant cross-reactivity or interference between Phospholipase A2 Group VII (LpPLA2) and analogues was observed.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStability\u003c\/b\u003e: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.\nTo minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay procedure summary\u003c\/b\u003e: 1. Prepare all reagents, samples and standards;\n2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;\n3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;\n4. Aspirate and wash 3 times;\n5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;\n6. Aspirate and wash 5 times;\n7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;\n8. Add 50µL Stop Solution. Read at 450nm immediately.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTest principle\u003c\/b\u003e: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Phospholipase A2 Group VII (LpPLA2). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Phospholipase A2 Group VII (LpPLA2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Phospholipase A2 Group VII (LpPLA2), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Phospholipase A2 Group VII (LpPLA2) in the samples is then determined by comparing the O.D. of the samples to the standard curve.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eResearch Area\u003c\/b\u003e: Enzyme \u0026amp; Kinase;Metabolic pathway;Infection immunity;\u003c\/p\u003e\u003cp\u003e\u003cb\u003eReferences Citing This Product\u003c\/b\u003e: \u003ca href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0765159710000262\"\u003eThe effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women\u003c\/a\u003e\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/online.liebertpub.com\/doi\/abs\/10.1089\/met.2011.0111\"\u003eAssociation of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22240497\"\u003eEffects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3759413\/\"\u003eEffects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23958269\"\u003eEverolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.hindawi.com\/journals\/jdr\/2014\/278063\/abs\/\"\u003eLipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/file.scirp.org\/Html\/15-8202855_47116.htm\"\u003eThe Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/link.springer.com\/article\/10.1134\/S1062359015010112\"\u003eIn vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24397392\"\u003eLipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24818163\"\u003eLipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25034387\"\u003eEffects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26374297\"\u003eEffect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/search.ebscohost.com\/login.aspx?direct=true\u0026amp;profile=ehost\u0026amp;scope=site\u0026amp;authtype=crawler\u0026amp;jrnl=00090514\u0026amp;AN=110723148\u0026amp;h=m0xSKuLLzFAHpP68AaY9CkcNZYGUG13sfJiiMF7zxsutbZsQiIItSLucGfiuXaRkppeeycbc%2F38jRj%2F2Rq32pQ%3D%3D\u0026amp;crl=c\"\u003eV\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4803547\/\"\u003eEffect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25773594\"\u003eEffect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-016-0368-3\"\u003eEffect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly …\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/search.ebscohost.com\/login.aspx?direct=true\u0026amp;profile=ehost\u0026amp;scope=site\u0026amp;authtype=crawler\u0026amp;jrnl=18410987\u0026amp;AN=129359477\u0026amp;h=uZUGA2wl9xcqhmQWswepQQJouj8KXPxELZeK8Fb9ovM3TuJHuwVGHwWNGhl%2F4%2FzFKdGq9EO6KwYaY8Y7P4doMQ%3D%3D\u0026amp;crl=c\"\u003eSERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"\"\u003eBiomarker for diagnosis of moyamoya disease\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32859455\/\"\u003eCirculating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/cnjournal.biomedcentral.com\/articles\/10.1186\/s41016-020-00188-z\"\u003eCan admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":48696722030692,"sku":"SEA867Hu","price":897.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_6ef6dfac-9d56-46a0-a0e8-bbd5133faf20.jpg?v=1783135089","url":"https:\/\/www.genebiosystems.com\/en-fr\/products\/lppla2-elisa-kit-for-human","provider":"GeneBio ","version":"1.0","type":"link"}